# NBTXR3 Nanoparticles and EBRT or EBRT With Brachytherapy in the Treatment of Prostate Adenocarcinoma

> **NCT02805894** · PHASE1,PHASE2 · TERMINATED · sponsor: **Nanobiotix** · enrollment: 5 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** NBTXR3 activated by IMRT only
- **DRUG:** NBTXR3 activated by Brachytherapy & IMRT

## Key facts

- **NCT ID:** NCT02805894
- **Lead sponsor:** Nanobiotix
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-11-15
- **Primary completion:** 2020-03-19
- **Final completion:** 2020-03-19
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Prostate cancer treatment has greatly changed since the initiation of this trial and therefore we have stopped this trial to allow for further evaluation of the treatment landscape
- **Last updated:** 2021-05-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02805894

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02805894, "NBTXR3 Nanoparticles and EBRT or EBRT With Brachytherapy in the Treatment of Prostate Adenocarcinoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02805894. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*